SIGN UP
LOG IN
News
CSTL
19.23
-4.14%
-0.83
Weekly Report: what happened at CSTL last week (0408-0412)?
Weekly Report · 1d ago
Press Release: Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024
Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024. The company will release its financial results for the first quarter ended March 31, 2024, after the close of market. Company management will host a conference call and webcast to discuss the financial results on the same day. Castle is a company improving health through innovative tests that guide patient care.
Dow Jones · 5d ago
Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations
Castle Biosciences recognizes the importance of Esophageal Cancer Awareness Month. The company is supporting key programs and initiatives throughout the month of April. Castle is collaborating with the Esophages Cancer Action Network, Gastro Broadcast podcast and EndoscopyNow to help advance cancer research, prevention and education.
Barchart · 5d ago
Weekly Report: what happened at CSTL last week (0401-0405)?
Weekly Report · 04/08 10:50
Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer
Castle Biosciences, Inc. Will share new data at the 20th European Association of Dermato-Oncology Congress. Castle will present data on its DecisionDx-Melanoma and Decisiondx-SCC tests. The company says the tests can help guide patient care decisions.
Barchart · 04/04 15:30
Weekly Report: what happened at CSTL last week (0325-0329)?
Weekly Report · 04/01 10:48
Castle Biosciences Secures Loan and Reshuffles Board
TipRanks · 03/27 21:23
*Castle Biosciences: Rodney Cotton Appointed to Bd of Directors, Effective Immediately, and Will Stand for Election at Annual Meeting >CSTL
Dow Jones · 03/27 21:01
*Castle Biosciences: Mara G. Aspinall Will Not Stand for Re-Election to Its Bd >CSTL
Dow Jones · 03/27 21:01
Castle Biosciences Announces Updates to its Board of Directors
Rodney Cotton has been appointed to Castle Biosciences' board of directors. Cotton is a leader in the diagnostics industry. He will stand for election at Castle's 2024 Annual Meeting. Mara G. Aspinall will not stand for re-election to Castle's board.
Barchart · 03/27 16:00
Weekly Report: what happened at CSTL last week (0318-0322)?
Weekly Report · 03/25 10:51
Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year
Castle Biosciences ranked 28th among 370 participating U.S. Companies with 500-999 employees. The company has received a Top Workplaces USA award for the third consecutive year. The national award program by Energage and USA Today celebrates organizations that have built exceptional workplace cultures.
Barchart · 03/25 06:00
Castle Biosciences Gives Long-Term Outcomes Data Shared At SSO 2024 Show That Patients With A Low-Risk DecisionDx-Melanoma Test Result Were Recurrence Free At 3-Years, Including Those Who Utilized The Test To Help Guide the Decision To Avoid An SLNB
Castle Biosciences' DecisionDx-Melanoma test shows clinical use value in patients with cutaneous melanoma. The test can identify high-risk patients who could consider a more intensive treatment pathway. Study of 979 patients will be presented at Society of Surgical Oncology 2024 Annual Meeting.
Benzinga · 03/22 20:34
Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB
Castle Biosciences' DecisionDx-Melanoma test is being presented at the Society of Surgical Oncology 2024 Annual Meeting in Atlanta. The test helps identify patients at high risk of sentinel lymph node (SLN) positivity in patients with melanoma. Study shows the test is a strong and independent predictor of metastasis.
Barchart · 03/22 15:30
Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy
Castle Biosciences' DecisionDx-SCC test to be used in clinical decision-making regarding the use of ART. Expert consensus article published in the Journal of Clinical and Aesthetic Dermatology. The consensus guidelines outline a recommended risk-based workflow to improve precision in ART recommendations. The test can help identify patients at high risk of metastasis who may benefit from ART.
Barchart · 03/19 06:00
Weekly Report: what happened at CSTL last week (0311-0315)?
Weekly Report · 03/18 10:49
AVLX, SGH and ETNB are among pre market losers
On the Move AVLX, SGH and ETNB are among pre market losers. 89bio and iHeartMedia are among the pre market gainers. CERo Therapeutics Holdings and Castle Biosciences are among those that lost in the biotech sector.
Seeking Alpha · 03/15 20:48
Castle Biosciences New Study Showing The Drug-Drug Interactions And Lifestyle Factors Provided By ' IDgenetix Test Improve Medication Recommendations Over Drug-Gene Interactions Alone For Patients 65 And Older
Castle Biosciences' IDgenetix pharmacogenomic test guides medication recommendations for patients with mental health conditions who are 65 and older. Study shows one-third of medication recommendations were due to drug-drug interactions and lifestyle factors. Majority of patients in the study were on five or more medications at the time of testing.
Benzinga · 03/15 20:34
Bio-Techne and Qiagen had the biggest increase in short interest levels last month - Baird
Seeking Alpha · 03/13 18:01
Weekly Report: what happened at CSTL last week (0304-0308)?
Weekly Report · 03/11 10:47
More
Webull provides a variety of real-time CSTL stock news. You can receive the latest news about Castle Biosciences through multiple platforms. This information may help you make smarter investment decisions.
About CSTL
Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Its portfolio consists of tests for skin cancers, uveal melanoma, Barretts esophagus and mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, and DecisionDx-UM, IDgenetix. DecisionDx-Melanoma is a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis, or recurrence, for patients diagnosed with invasive cutaneous melanoma (CM), a deadly skin cancer. MyPath Melanoma is GEP test offering for patients with difficult-to-diagnose melanocytic lesions. IDgenetix is pharmacogenomics (PGx) test that helps to guide optimal drug treatment for patients diagnosed with major depressive disorder, bipolar disorder, and other.